These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2116226)

  • 21. [The prevention of the myocardial toxicity of doxorubicin with superoxide dismutase].
    Villani F; Galimberti M; Favalli L; Rozza A; Lanza E; Poggi P
    G Ital Cardiol; 1991 Jun; 21(6):633-41. PubMed ID: 1743445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits.
    Herman EH; Ferrans VJ
    Cancer Chemother Pharmacol; 1986; 16(2):102-6. PubMed ID: 3081268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).
    Hasinoff BB
    Agents Actions; 1990 Mar; 29(3-4):374-81. PubMed ID: 2160191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.
    Herman EH; el-Hage A; Ferrans VJ
    Toxicol Appl Pharmacol; 1988 Jan; 92(1):42-53. PubMed ID: 3124293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)-1,2,-bis (3-5-dioxopiperazinyl-1-yl) propane (ICRF 187), on murine sarcoma S180 in vitro.
    Wadler S; Green MD; Basch R; Muggia FM
    Biochem Pharmacol; 1987 May; 36(9):1495-501. PubMed ID: 3107574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat.
    Villani F; Galimberti M; Monti E; Cova D; Lanza E; Rozza-Dionigi A; Favalli L; Poggi P
    Toxicol Appl Pharmacol; 1990 Feb; 102(2):292-9. PubMed ID: 2105541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
    Speyer JL; Green MD; Kramer E; Rey M; Sanger J; Ward C; Dubin N; Ferrans V; Stecy P; Zeleniuch-Jacquotte A
    N Engl J Med; 1988 Sep; 319(12):745-52. PubMed ID: 3137469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of doxorubicin on hepatic and cardiac glutathione.
    Doroshow JH; Locker GY; Baldinger J; Myers CE
    Res Commun Chem Pathol Pharmacol; 1979 Nov; 26(2):285-95. PubMed ID: 574979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prenatal effects of the cancer chemotherapeutic drug ICRF 159 in mice, rats, and rabbits.
    Duke DI
    Teratology; 1975 Feb; 11(1):119-26. PubMed ID: 1138404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of lipid peroxidation in acute doxorubicin-induced cardiotoxicity as studied in rat isolated heart.
    Julicher RH; Sterrenberg L; Bast A; Riksen RO; Koomen JM; Noordhoek J
    J Pharm Pharmacol; 1986 Apr; 38(4):277-82. PubMed ID: 2872291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of trimetazidine on early and delayed doxorubicin myocardial toxicity.
    Perletti G; Monti E; Paracchini L; Piccinini F
    Arch Int Pharmacodyn Ther; 1989; 302():280-9. PubMed ID: 2636823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies.
    Green MD; Alderton P; Sobol MM; Gross J; Muggia FM; Speyer JL
    Cancer Treat Res; 1991; 58():101-17. PubMed ID: 1683780
    [No Abstract]   [Full Text] [Related]  

  • 34. ICRF-187 and doxorubicin-induced cardiac toxicity.
    N Engl J Med; 1989 Feb; 320(6):399-400. PubMed ID: 2492370
    [No Abstract]   [Full Text] [Related]  

  • 35. Enhancement of experimental lung metastases by cultured B16 melanoma cells treated with (+/-)-1,2-bis(3,5-dioxopiperazin-1-y)propane (ICRF-159).
    Lazo JS; Ingber DE; Sartorelli AC
    Cancer Res; 1978 Aug; 38(8):2263-70. PubMed ID: 667822
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of adriamycin on the activities of superoxide dismutase, glutathione peroxidase and catalase in tissues of mice.
    Sazuka Y; Tanizawa H; Takino Y
    Jpn J Cancer Res; 1989 Jan; 80(1):89-94. PubMed ID: 2496064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis-(3,5-dioxo-piperazin-1-yl)propane] onto an existing ferric-anthracycline complex.
    Sobol MM; Amiet RG; Green MD
    Mol Pharmacol; 1992 Jan; 41(1):8-17. PubMed ID: 1732725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer.
    Speyer JL; Green MD; Sanger J; Zeleniuch-Jacquotte A; Kramer E; Rey M; Wernz JC; Blum RH; Hochester H; Meyers M
    Cancer Treat Rev; 1990 Sep; 17(2-3):161-3. PubMed ID: 2125531
    [No Abstract]   [Full Text] [Related]  

  • 39. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse.
    Bertazzoli C; Bellini O; Magrini U; Tosana MG
    Cancer Treat Rep; 1979; 63(11-12):1877-83. PubMed ID: 526920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529.
    Agen C; Bernardini N; Danesi R; Della Torre P; Costa M; Del Tacca M
    Cancer Chemother Pharmacol; 1992; 30(2):95-9. PubMed ID: 1600601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.